Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
Aurion Biotech has appointed Donald Munoz as Chief Financial Officer, reporting to CEO Greg Kunst. Munoz brings over 30 years of healthcare experience, including nine years as CFO of NuCana plc (NASDAQ: NCNA), where he led a $114 million IPO and $80 million follow-on offering. Previously, he served as CFO at NOXXON Pharma and spent 20 years as a healthcare investment banker at firms including Cowen & Company, Leerink Partners, and Deutsche Bank.
At NuCana, Munoz managed financial operations, investor relations, SEC reporting, audit, tax, and financial planning. Throughout his career, he has completed over 100 financing and strategic advisory transactions. The appointment follows Aurion's announcement of positive six-month top-line data from its CLARA Phase 1/2 clinical trial for AURN001, their lead product candidate targeting corneal endothelial disease.
Aurion Biotech ha nominato Donald Munoz come Chief Financial Officer, riportando direttamente al CEO Greg Kunst. Munoz porta con sé oltre 30 anni di esperienza nel settore sanitario, inclusi nove anni come CFO di NuCana plc (NASDAQ: NCNA), dove ha guidato un'IPO da 114 milioni di dollari e un'offerta successiva da 80 milioni di dollari. In precedenza, ha ricoperto il ruolo di CFO presso NOXXON Pharma e ha trascorso 20 anni come banchiere d'investimento nel settore sanitario presso aziende come Cowen & Company, Leerink Partners e Deutsche Bank.
Presso NuCana, Munoz ha gestito le operazioni finanziarie, le relazioni con gli investitori, la reportistica SEC, la revisione contabile, le tasse e la pianificazione finanziaria. Nel corso della sua carriera, ha completato oltre 100 transazioni di finanziamento e consulenza strategica. La nomina segue l'annuncio di Aurion riguardo dati positivi preliminari a sei mesi dal suo studio clinico CLARA di Fase 1/2 per AURN001, il loro principale candidato prodotto mirato a trattare le malattie endoteliali corneali.
Aurion Biotech ha nombrado a Donald Munoz como Director Financiero, reportando al CEO Greg Kunst. Munoz aporta más de 30 años de experiencia en el sector salud, incluidos nueve años como CFO de NuCana plc (NASDAQ: NCNA), donde lideró una OPI de 114 millones de dólares y una oferta adicional de 80 millones de dólares. Anteriormente, fue CFO en NOXXON Pharma y pasó 20 años como banquero de inversión en salud en empresas como Cowen & Company, Leerink Partners y Deutsche Bank.
En NuCana, Munoz gestionó las operaciones financieras, las relaciones con los inversores, la presentación de informes a la SEC, las auditorías, los impuestos y la planificación financiera. A lo largo de su carrera, ha completado más de 100 transacciones de financiamiento y asesoramiento estratégico. La nominación sigue al anuncio de Aurion sobre datos positivos preliminares a seis meses de su ensayo clínico CLARA de Fase 1/2 para AURN001, su principal candidato a producto dirigido a enfermedades endoteliales corneales.
아우리온 바이오텍은 도날드 무노즈를 최고 재무 책임자(CFO)로 임명하였으며, CEO인 그렉 쿤스트에게 보고합니다. 무노즈는 30년 이상의 의료 분야 경험을 보유하고 있으며, 그 중 9년은 누카나 plc (NASDAQ: NCNA)의 CFO로 근무하며 1억 1,400만 달러 규모의 IPO와 8,000만 달러의 후속 제안을 주도했습니다. 이전에는 NOXXON Pharma에서 CFO로 근무하였고, Cowen & Company, Leerink Partners, 그리고 Deutsche Bank와 같은 회사에서 20년간 의료 투자은행업에 종사했습니다.
누카나에서 무노즈는 재무 운영, 투자자 관계, SEC 보고, 감사, 세금, 재무 계획 등을 관리했습니다. 그의 경력 동안 그는 100건 이상의 자금 조달 및 전략 자문 거래를 완료했습니다. 이번 임명은 아우리온이 AURN001의 CLARA 1/2 단계 임상 시험에서 6개월 간의 긍정적인 데이터를 발표한 후 이루어졌습니다. AURN001은 각막 내피 질환을 목표로 하는 주요 제품 후보입니다.
Aurion Biotech a nommé Donald Munoz au poste de Directeur Financier, rendant compte au PDG Greg Kunst. Munoz apporte plus de 30 ans d'expérience dans le secteur de la santé, dont neuf ans en tant que directeur financier de NuCana plc (NASDAQ: NCNA), où il a dirigé une introduction en bourse de 114 millions de dollars et une offre subséquente de 80 millions de dollars. Auparavant, il a été directeur financier chez NOXXON Pharma et a passé 20 ans en tant que banquier d'investissement dans le secteur de la santé chez des sociétés telles que Cowen & Company, Leerink Partners et Deutsche Bank.
Chez NuCana, Munoz a géré les opérations financières, les relations avec les investisseurs, les rapports auprès de la SEC, les audits, la fiscalité et la planification financière. Au cours de sa carrière, il a réalisé plus de 100 transactions de financement et de conseil stratégique. Cette nomination fait suite à l'annonce d'Aurion concernant des données préliminaires positives à six mois de son essai clinique CLARA de Phase 1/2 pour AURN001, leur principal candidat produit visant les maladies de l'endothélium cornéen.
Aurion Biotech hat Donald Munoz zum Chief Financial Officer ernannt, der dem CEO Greg Kunst berichtet. Munoz bringt über 30 Jahre Erfahrung im Gesundheitswesen mit, darunter neun Jahre als CFO von NuCana plc (NASDAQ: NCNA), wo er einen Börsengang über 114 Millionen Dollar und eine Folgefinanzierung über 80 Millionen Dollar leitete. Zuvor war er CFO bei NOXXON Pharma und verbrachte 20 Jahre als Investmentbanker im Gesundheitswesen bei Firmen wie Cowen & Company, Leerink Partners und Deutsche Bank.
Bei NuCana war Munoz für die finanziellen Abläufe, die Beziehungen zu Investoren, die SEC-Berichterstattung, die Prüfung, die Steuern und die Finanzplanung verantwortlich. In seiner Karriere hat er über 100 Finanzierungs- und strategische Beratungsaufträge erfolgreich abgeschlossen. Die Ernennung folgt auf die Ankündigung von Aurion, positive erste Ergebnisse aus der sechsmonatigen CLARA Phase 1/2-Studie für AURN001, ihrem Hauptproduktkandidaten zur Bekämpfung von Erkrankungen der Hornhautendothelzellen, bekannt zu geben.
- Appointment of seasoned CFO with extensive healthcare and biotech experience
- New CFO has successful track record of major capital raises ($114M IPO, $80M follow-on)
- Recent positive Phase 1/2 clinical trial results for lead product AURN001
- None.
Experienced Healthcare Executive to Lead Finance Organization
“We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion’s CEO. “Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as a healthcare investment banker, make him an ideal addition to Aurion.”
“I’m thrilled to join Aurion as CFO,” said Don Munoz. “I believe that Aurion’s lead product candidate, AURN001, has significant potential to treat corneal endothelial disease, which can lead to blindness. I look forward to working with the Aurion team to pursue bringing this cell therapy to patients in need.”
Donald Munoz has over 30 years of health care experience as a chief financial officer and an investment banker. Prior to joining Aurion, Don spent more than nine years as chief financial officer of NuCana plc (NASDAQ: NCNA) (NuCana), a publicly traded biotechnology company developing oncology therapeutics. At NuCana, Don oversaw financial management, investor relations, Securities and Exchange Commission reporting, audit, tax and financial planning and analysis. Don also led NuCana’s
Don’s appointment follows Aurion’s announcement of positive six-month top-line data from its CLARA Phase 1/2 clinical trial in
About Aurion Biotech, Inc.
Aurion’s mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech in 2022. Aurion is advancing AURN001, an investigational, single-administration, allogeneic cell therapy to treat corneal edema secondary to corneal endothelial dysfunction. Aurion developed and has launched the first commercially available corneal endothelial cell therapy in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210293269/en/
Media Contacts:
Judith McGarry
(Corporate Communications)
415-971-2900
judith.mcgarry@aurionbiotech.com
Michele Gray
(Ophthalmology Media)
917-449-9250
michele@mgraycommunications.com
Beth Keshishian
(Biotech & Business Media)
917-912-7195
beth@bethkeshishian.com
Source: Aurion Biotech, Inc.
FAQ
What experience does Donald Munoz bring to Aurion Biotech as new CFO?
What were Donald Munoz's key achievements at NuCana (NASDAQ: NCNA)?
What is Aurion Biotech's lead product candidate?
What recent clinical trial results has Aurion Biotech announced?
